Evidence map›Paper›PMID 25819886›Full record

ArticleNanomedicine : nanotechnology, biology, and medicine2015

Aerosol droplet delivery of mesoporous silica nanoparticles: A strategy for respiratory-based therapeutics.

Xueting Li, Min Xue, Otto G Raabe, Holly L Aaron, Ellen A Eisen, James E Evans, Fred A Hayes, Sumire Inaga, Abderrahmane Tagmount, Minoru Takeuchi and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nanomedicine : nanotechnology, biology, and medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Mesoporous Silica Nanoparticles as Drug Delivery Systems.Pharmaceuticals (Basel, Switzerland) · 2025
    Review
  3. Review
  4. Review
  5. The emergence of nanoporous materials in lung cancer therapy.Science and technology of advanced materials · 2022
    Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Xueting LiCenter for Health and the Environment, University of California, Davis, USA; Department of Nutritional Sciences and Toxicology, University of California, Berkeley, USA; Department of Chemical Engineering and Materials Science, University of California, Davis, USA. Electronic address: xl2479@columbia.edu.
Min XueDepartment of Chemistry and Biochemistry, University of California, Los Angeles, USA. Electronic address: mxue@chem.ucla.edu.
Otto G RaabeCenter for Health and the Environment, University of California, Davis, USA; Department of Molecular Biosciences, University of California, Davis, USA. Electronic address: ograabe@ucdavis.edu.
Holly L AaronCancer Research Laboratory Molecular Imaging Center, University of California, Berkeley, USA. Electronic address: hollya@berkeley.edu.
Ellen A EisenEnvironmental Health Sciences, School of Public Health, University of California, Berkeley, USA. Electronic address: eeisen@berkeley.edu.
James E EvansCenter for Health and the Environment, University of California, Davis, USA. Electronic address: james.evans@pnnl.gov.
Fred A HayesDepartment of Chemical Engineering and Materials Science, University of California, Davis, USA. Electronic address: fahayes@ucdavis.edu.
Sumire InagaDepartment of Functional, Morphological and Regulatory Science, Tottori University, Yonago, Japan. Electronic address: sumire@med.tottori-u.ac.jp.
Abderrahmane TagmountDepartment of Nutritional Sciences and Toxicology, University of California, Berkeley, USA. Electronic address: tagmount@berkeley.edu.
Minoru TakeuchiDepartment of Animal Medical Science, Kyoto Sangyo University, Kyoto, Japan. Electronic address: mtakex@cc.kyoto-su.ac.jp.
Chris VulpeDepartment of Nutritional Sciences and Toxicology, University of California, Berkeley, USA. Electronic address: vulpe@berkeley.edu.
Jeffrey I ZinkDepartment of Chemistry and Biochemistry, University of California, Los Angeles, USA. Electronic address: Zink@chem.ucla.edu.
Subhash H RisbudDepartment of Chemical Engineering and Materials Science, University of California, Davis, USA. Electronic address: shrisbud@ucdavis.edu.
Kent E PinkertonCenter for Health and the Environment, University of California, Davis, USA. Electronic address: kepinkerton@ucdavis.edu.

Funding

National Institute on Aging (NIA) ColonyP51OD011107 · OD · UNIVERSITY OF CALIFORNIA AT DAVIS · PI Simon J. Atkinson · 2012 to 2026
$191.5M
The Western Center for Agricultural Health and Safety at UC DavisU50OH007550 · OH · UNIVERSITY OF CALIFORNIA DAVIS · PI SCHENKER, MARC B · 2001 to 2010
$5.4M
Engineered Nanomaterials: Linking Physical and Chemical Properties to BiologyU01ES020127 · NIEHS · UNIVERSITY OF CALIFORNIA AT DAVIS · PI PINKERTON, KENT ED · 2010 to 2014
$2.5M
NIEHS NIH HHS U01 ES 020127NIEHS NIH HHS U01 ES020127NIH HHS P51 OD011107NIOSH CDC HHS U50 OH007550
6 · The paper itself

Abstract

A highly versatile nanoplatform that couples mesoporous silica nanoparticles (MSNs) with an aerosol technology to achieve direct nanoscale delivery to the respiratory tract is described. This novel method can deposit MSN nanoparticles throughout the entire respiratory tract, including nasal, tracheobronchial and pulmonary regions using a water-based aerosol. This delivery method was successfully tested in mice by inhalation. The MSN nanoparticles used have the potential for carrying and delivering therapeutic agents to highly specific target sites of the respiratory tract. The approach provides a critical foundation for developing therapeutic treatment protocols for a wide range of diseases where aerosol delivery to the respiratory system would be desirable. FROM THE CLINICAL EDITOR: Delivery of drugs via the respiratory tract is an attractive route of administration. In this article, the authors described the design of mesoporous silica nanoparticles which could act as carriers for drugs. The underlying efficacy was successfully tested in a mouse model. This drug-carrier inhalation nanotechnology should potentially be useful in human clinical setting in the future.

Indexed as

AerosolsNanoparticlesAdministration, InhalationAnimalsBronchoalveolar Lavage FluidLung DiseasesMaleMiceMicroscopy, Electron, TransmissionSilicon DioxideAerosolsSilicon DioxideAerosol dropletsMesoporous silica nanoparticlesRespiratory tract

Identifiers

PMID25819886
PMCPMC4494876

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.